HC Wainwright Comments on Neurogene FY2027 Earnings

Neurogene Inc. (NASDAQ:NGNE) – Investment analysts at HC Wainwright issued their FY2027 earnings per share (EPS) estimates for shares of Neurogene in a research report issued to clients and investors on Thursday, March 26th. HC Wainwright analyst M. Kapoor expects that the company will earn ($4.93) per share for the year. HC Wainwright currently has a “Buy” rating and a $70.00 price objective on the stock. The consensus estimate for Neurogene’s current full-year earnings is ($4.27) per share.

NGNE has been the subject of several other research reports. Lifesci Capital began coverage on Neurogene in a research report on Monday, January 26th. They set an “outperform” rating and a $50.00 price objective for the company. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Neurogene in a research report on Thursday, January 22nd. Canaccord Genuity Group initiated coverage on shares of Neurogene in a research note on Friday, February 27th. They issued a “buy” rating for the company. Finally, Wall Street Zen cut shares of Neurogene from a “hold” rating to a “sell” rating in a research report on Saturday, December 13th. Five equities research analysts have rated the stock with a Buy rating, one has given a Hold rating and one has given a Sell rating to the company. According to data from MarketBeat, the stock has a consensus rating of “Moderate Buy” and an average target price of $44.00.

Neurogene Stock Down 5.0%

Shares of NGNE stock opened at $20.35 on Friday. The stock has a market cap of $316.85 million, a price-to-earnings ratio of -4.80 and a beta of 1.53. The business’s fifty day moving average is $19.52 and its 200 day moving average is $21.67. Neurogene has a twelve month low of $6.88 and a twelve month high of $37.27.

Neurogene (NASDAQ:NGNE) last released its earnings results on Tuesday, March 24th. The company reported ($1.12) EPS for the quarter, beating analysts’ consensus estimates of ($1.20) by $0.08.

Hedge Funds Weigh In On Neurogene

A number of hedge funds have recently bought and sold shares of NGNE. Balyasny Asset Management L.P. bought a new stake in Neurogene during the 3rd quarter valued at about $12,114,000. Logos Global Management LP bought a new position in shares of Neurogene in the fourth quarter worth approximately $4,017,000. Jennison Associates LLC grew its holdings in shares of Neurogene by 35.3% during the fourth quarter. Jennison Associates LLC now owns 533,088 shares of the company’s stock valued at $10,982,000 after buying an additional 138,999 shares during the last quarter. State Street Corp grew its holdings in shares of Neurogene by 47.8% during the fourth quarter. State Street Corp now owns 307,797 shares of the company’s stock valued at $6,341,000 after buying an additional 99,487 shares during the last quarter. Finally, Goldman Sachs Group Inc. increased its position in shares of Neurogene by 122.5% during the fourth quarter. Goldman Sachs Group Inc. now owns 162,018 shares of the company’s stock valued at $3,338,000 after acquiring an additional 89,216 shares in the last quarter. Institutional investors own 52.37% of the company’s stock.

Insider Buying and Selling

In other Neurogene news, insider Stuart Cobb sold 6,797 shares of Neurogene stock in a transaction on Friday, March 13th. The stock was sold at an average price of $20.81, for a total transaction of $141,445.57. Following the completion of the transaction, the insider owned 30,497 shares in the company, valued at approximately $634,642.57. The trade was a 18.23% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, CFO Christine Mikail Cvijic sold 4,045 shares of the business’s stock in a transaction on Friday, March 13th. The stock was sold at an average price of $20.81, for a total value of $84,176.45. Following the completion of the sale, the chief financial officer directly owned 105,798 shares in the company, valued at $2,201,656.38. This trade represents a 3.68% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. 11.64% of the stock is owned by company insiders.

Key Headlines Impacting Neurogene

Here are the key news stories impacting Neurogene this week:

• Positive Sentiment: HC Wainwright reiterated a “Buy” rating and set a $70 price objective for NGNE, providing bullish analyst support even as it modeled FY2027 EPS of ($4.93). This endorsement and high target can help underpin longer-term upside. HC Wainwright Buy/$70 Target
• Positive Sentiment: An MSN/aggregated report flagged a substantial analyst-driven price-target increase (reported as a 37.29% rise to 82.62), signaling at least one firm is materially more optimistic on Neurogene’s longer-term value — a clear positive for investor sentiment and potential catalyst for upside. Neurogene (NGNE) price target increased by 37.29% to 82.62
• Neutral Sentiment: A Globe and Mail roundup included Neurogene in a broader analysts-insights piece; such coverage can raise visibility but didn’t add new company-specific data likely to move the stock by itself. Analysts Offer Insights on Healthcare Companies
• Negative Sentiment: Lifesci Capital cut Q1–Q4 2026 and FY2026 EPS estimates for NGNE across multiple notes, lowering FY2026 EPS to ($4.59) (from $4.33) while still keeping an “Outperform” rating and a $50 target. Those downward revisions to near-term profitability are a bearish driver and likely the primary reason for today’s weakness. Lifesci Capital EPS revisions / Outperform $50

Neurogene Company Profile

Neurogene, Inc is a clinical‐stage biotechnology company specializing in the development of gene therapies for rare neurological diseases. The company’s lead platform employs adeno‐associated virus (AAV) vectors designed to deliver functional copies of disease-causing genes directly to the central nervous system. Neurogene’s pipeline focuses on inherited lysosomal storage disorders, including investigational programs for GM1 and GM2 gangliosidoses, with additional preclinical efforts targeting other monogenic neurodegenerative conditions.

Neurogene’s proprietary AAV9‐based delivery system has been engineered to cross the blood-brain barrier, aiming to provide durable gene expression in affected tissues.